Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Stock Has Average Price Target of $32.83 According to Analysts

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) has been given an average rating of “Moderate Buy” by the eight research firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $32.83.

CRVS has been the subject of several analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a research report on Monday, October 26th. Mizuho set a $27.00 price objective on Corvus Pharmaceuticals in a research note on Thursday, October 29th. Wall Street Zen lowered Corvus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, November 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of Corvus Pharmaceuticals in a research note on Wednesday, September 16th. Finally, Ladenburg Thalmann & Co. Inc. upgraded Corvus Pharmaceuticals to a “strong-buy” rating in a report on Thursday, July 30th.

Check Out Our Latest Report on Corvus Pharmaceuticals

Insider Buying and Selling

In related news, insider Jeffrey Arcara acquired 3,000 shares of the stock in a transaction on Wednesday, November 11th. The stock was purchased at an average price of $11.46 per share, for a total transaction of $34,380.00. Following the completion of the transaction, the insider owned 3,000 shares of the company’s stock, valued at $34,380. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last 90 days, insiders purchased 4,500 shares of company stock valued at $50,478. 19.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Corvus Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in CRVS. The Manufacturers Life Insurance Company raised its stake in shares of Corvus Pharmaceuticals by 481.7% during the first quarter. The Manufacturers Life Insurance Company now owns 101,779 shares of the company’s stock valued at $1,489,000 after acquiring an additional 84,282 shares during the last quarter. DCF Advisers LLC bought a new stake in shares of Corvus Pharmaceuticals in the second quarter worth about $9,524,000. Blue Owl Capital Holdings LP bought a new stake in shares of Corvus Pharmaceuticals in the second quarter worth about $9,092,000. Renaissance Technologies LLC purchased a new position in Corvus Pharmaceuticals during the 1st quarter valued at about $1,190,000. Finally, Bank of America Corp DE purchased a new position in Corvus Pharmaceuticals during the 2nd quarter valued at about $11,322,000. Hedge funds and other institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Stock Performance

Shares of Corvus Pharmaceuticals stock opened at $9.66 on Tuesday. Corvus Pharmaceuticals has a 52-week low of $6.39 and a 52-week high of $26.95. The stock has a market capitalization of $814.99 million, a price-to-earnings ratio of -13.61 and a beta of 1.57. The company has a fifty day moving average of $10.84 and a 200-day moving average of $13.77.

Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). On average, equities research analysts forecast that Corvus Pharmaceuticals will post -0.81 earnings per share for the current fiscal year.

Corvus Pharmaceuticals Company Profile

(Get Free Report)

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines that target the immune system to treat cancer and immune-related diseases. The company is based in Burlingame, California, and its work centers on therapies in clinical development rather than marketed products. Its lead candidate, soquelitinib (also known as CPI-818), is an oral inhibitor of interleukin-2-inducible T-cell kinase, or ITK. Corvus is developing the drug for T-cell lymphoma and has also explored its potential in inflammatory and autoimmune conditions, including atopic dermatitis.

See Also

Analyst Recommendations for Corvus Pharmaceuticals (NASDAQ:CRVS)

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.